二重特異性抗体治療薬受託製造の世界市場規模調査＆予測、適応症別、投与経路別、最終用途別、地域別分析、2023-2030年

世界の二重特異性抗体治療薬受託製造市場は、2022年に約52億9,000万米ドルと評価され、予測期間2023-2030年には36.4％以上の健全な成長率で成長すると予測されています。

二重特異性抗体治療薬受託製造とは、二重特異性抗体の製造に関わる製造工程を専門の受託製造機関（CMO）に委託することを指します。二重特異性抗体は、がん、自己免疫疾患、感染症などの疾病に関与する細胞表面にしばしば存在する2つの異なる抗原を同時に標的とするために創製された治療用分子群です。これらの抗体は、治療の特異性と有効性を高める能力があるため、大きな可能性を秘めています。がんや自己免疫疾患などの慢性疾患の増加、個別化医療に対する需要の急増、バイオ医薬品産業の世界化などが、世界の市場需要に拍車をかけている主な要因です。

さらに、二重特異性抗体治療薬のパイプラインが充実していることも、世界市場の成長に好影響を与えています。バイオ医薬品企業は、開発の様々な段階において開発期間を短縮するために、専属の受託製造業者に製造を委託することが多いです。BioPharm Internationalによると、二重特異性抗体治療薬の汎用性は、腫瘍免疫療法、神経疾患、標的ドラッグデリバリー、感染症など様々な臨床領域にわたっています。BioPharm Internationalによれば、二重特異性抗体治療薬は理想的には腫瘍免疫療法、標的ドラッグデリバリー、神経疾患、感染症など幅広い臨床応用が可能です。また、二重特異性抗体研究に対する熱意の高まりは、免疫療法、新規臨床試験、薬事承認への投資の高まりと相まって、市場の拡大をもたらしています。第I/II相臨床試験の結果によると、難治性または再発性の多発性骨髄腫患者に対して、二重特異性抗体REGN5459の奏効率は90.5％でした。ヒトを対象とした二重特異性抗体の調査結果は、2023年の米国がん学会年次総会でも報告されました。米国FDAは、REGN5459の新たな結果を受けて、BCMAとCD3を標的とする初の二重特異性抗体を持続性多発性骨髄腫患者に対して承認しました。同様に、サイノ・バイオロジカル社によると、最初に認可された二重特異性抗体（bsAB）であるカトゥマキソマブは、2022年時点でEMAおよび/またはFDAが認可したがん免疫療法用の6つのbsABのうちの1つです。このように、前述の要因が推定期間中の二重特異性抗体治療薬受託製造市場の成長を促進しています。さらに、現在進行中の二重特異性抗体治療薬の研究活動やバイオテクノロジーの技術進歩は、予測期間中に様々な有利な機会をもたらします。しかし、二重特異性抗体の製造に関連する規制上の課題や高コストが、2023-2030年の予測期間を通じて市場の成長を妨げています。

二重特異性抗体治療薬受託製造の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、医薬品開発コストの高さ、臨床試験数の増加、バイオテクノロジーの技術進歩、研究活動の活発化により、2022年の市場を独占しました。一方、アジア太平洋地域は予測期間中に最も高いCAGRで成長すると予想されます。二重特異性抗体に対する需要の増加、個別化医療に対する需要の高まり、がんの有病率の増加、中国、インド、日本を含む主要国における新薬の必要性などが、同地域全体の市場需要を大きく押し上げています。

本調査の目的は、近年のさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 世界の二重特異性抗体治療薬受託製造市場の定義と範囲

• 調査目的
• 市場の定義と範囲
  • 業界の進化
  • 調査範囲
• 調査対象年
• 通貨換算レート

第3章 二重特異性抗体治療薬受託製造の世界市場力学

• 二重特異性抗体治療薬受託製造市場の影響分析（2020-2030年）
  • 市場促進要因
    • 二重特異性抗体治療薬の強固なパイプライン
    • がんや自己免疫疾患などの慢性疾患の増加
  • 市場の課題
    • 規制上の課題
    • 二重特異性抗体の製造に伴う高コスト
  • 市場機会
    • 二重特異性抗体治療薬の継続的な研究活動
    • バイオテクノロジーにおける技術の進歩

第4章 世界の二重特異性抗体治療薬受託製造市場産業分析

• ポーターの5フォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターの5フォース影響分析
• PEST分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 環境
  • 法律
• 主な投資機会
• 主要成功戦略
• COVID-19影響分析
• 破壊的動向
• 業界専門家の視点
• アナリストの結論・提言

第5章 二重特異性抗体治療薬受託製造の世界市場：適応症別

• 市場スナップショット
• 二重特異性抗体治療薬受託製造の世界市場：適応症別、実績 - ポテンシャル分析
• 二重特異性抗体治療薬受託製造の世界市場：適応症別推定・予測 2020-2030年
• 二重特異性抗体治療薬受託製造市場、サブセグメント分析
  • がん
  • 感染症
  • 自己炎症性疾患および自己免疫疾患
  • 中枢神経系疾患
  • その他

第6章 二重特異性抗体治療薬受託製造の世界市場：投与経路別

• 市場スナップショット
• 二重特異性抗体治療薬受託製造の世界市場：投与経路別、実績 - ポテンシャル分析
• 二重特異性抗体治療薬受託製造の世界市場、投与経路別推定・予測 2020-2030年
• 二重特異性抗体治療薬受託製造市場、サブセグメント分析
  • 静脈内投与
  • 皮下投与
  • その他

第7章 二重特異性抗体治療薬受託製造の世界市場：最終用途別

• 市場スナップショット
• 二重特異性抗体治療薬受託製造の世界市場：最終用途別、実績 - ポテンシャル分析
• 二重特異性抗体治療薬受託製造の世界市場：最終用途別推定・予測 2020-2030年
• 二重特異性抗体治療薬受託製造市場、サブセグメント分析
  • 製薬企業
  • バイオ医薬品企業
  • その他

第8章 二重特異性抗体治療薬受託製造の世界市場：地域別分析

• 主要国
• 主な新興国
• 二重特異性抗体治療薬受託製造市場、地域別市場スナップショット
• 北米
  • 米国
    • 適応症の推定・予測、2020-2030年
    • 投与経路の推定・予測、2020～2030年
    • 最終用途の推定・予測、2020～2030年
  • カナダ
• 欧州の二重特異性抗体治療薬受託製造市場スナップショット
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋二重特異性抗体治療薬受託製造市場スナップショット
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカの二重特異性抗体治療薬受託製造市場スナップショット
  • ブラジル
  • メキシコ
• 中東・アフリカ
  • サウジアラビア
  • 南アフリカ
  • その他中東とアフリカ

第9章 競合情報

• 主要企業のSWOT分析
• 主要市場戦略
• 企業プロファイル
  • Lonza Group AG
    • 主要情報
    • 概要
    • 財務（データの入手可能性によります）
    • 製品概要
    • 最近の動向
  • F. Hoffmann-La Roche Ltd
  • Creative Biolabs Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Janssen Global Services, LLC
  • Johnson & Johnson Services, Inc
  • IQVIA Holdings Inc.
  • WuXi Biologics Holdings Co. Ltd.
  • Sino Biological Inc.

第10章 調査プロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • 検証
  • 出版
• 調査属性
• 調査前提条件

LIST OF TABLES

• TABLE 1. Global Bispecific Antibody Therapeutics Contract Manufacturing Market, report scope
• TABLE 2. Global Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by Region 2020-2030 (USD Billion)
• TABLE 3. Global Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by Indication 2020-2030 (USD Billion)
• TABLE 4. Global Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
• TABLE 5. Global Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by End-use 2020-2030 (USD Billion)
• TABLE 6. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 7. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 8. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 9. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 10. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 11. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 12. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 13. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 14. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 15. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 16. U.S. Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 17. U.S. Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 18. U.S. Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 19. Canada Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 20. Canada Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 21. Canada Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 22. UK Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 23. UK Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 24. UK Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 25. Germany Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 26. Germany Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 27. Germany Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 28. France Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 29. France Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 30. France Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 31. Italy Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 32. Italy Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 33. Italy Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 34. Spain Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 35. Spain Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 36. Spain Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 37. RoE Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 38. RoE Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 39. RoE Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 40. China Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 41. China Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 42. China Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 43. India Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 44. India Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 45. India Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 46. Japan Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 47. Japan Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 48. Japan Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 49. South Korea Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 50. South Korea Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 51. South Korea Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 52. Australia Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 53. Australia Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 54. Australia Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 55. RoAPAC Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 56. RoAPAC Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 57. RoAPAC Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 58. Brazil Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 59. Brazil Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 60. Brazil Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 61. Mexico Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 62. Mexico Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 63. Mexico Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 64. RoLA Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 65. RoLA Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 66. RoLA Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 67. Saudi Arabia Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 68. South Africa Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 69. RoMEA Bispecific Antibody Therapeutics Contract Manufacturing Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 70. List of secondary sources, used in the study of global Bispecific Antibody Therapeutics Contract Manufacturing Market
• TABLE 71. List of primary sources, used in the study of global Bispecific Antibody Therapeutics Contract Manufacturing Market
• TABLE 72. Years considered for the study
• TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

• FIG 1. Global Bispecific Antibody Therapeutics Contract Manufacturing Market, research methodology
• FIG 2. Global Bispecific Antibody Therapeutics Contract Manufacturing Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Bispecific Antibody Therapeutics Contract Manufacturing Market, key trends 2022
• FIG 5. Global Bispecific Antibody Therapeutics Contract Manufacturing Market, growth prospects 2023-2030
• FIG 6. Global Bispecific Antibody Therapeutics Contract Manufacturing Market, porters 5 force model
• FIG 7. Global Bispecific Antibody Therapeutics Contract Manufacturing Market, pest analysis
• FIG 8. Global Bispecific Antibody Therapeutics Contract Manufacturing Market, value chain analysis
• FIG 9. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by segment, 2020 & 2030 (USD Billion)
• FIG 10. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by segment, 2020 & 2030 (USD Billion)
• FIG 11. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by segment, 2020 & 2030 (USD Billion)
• FIG 12. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by segment, 2020 & 2030 (USD Billion)
• FIG 13. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by segment, 2020 & 2030 (USD Billion)
• FIG 14. Global Bispecific Antibody Therapeutics Contract Manufacturing Market, regional snapshot 2020 & 2030
• FIG 15. North America Bispecific Antibody Therapeutics Contract Manufacturing Market 2020 & 2030 (USD Billion)
• FIG 16. Europe Bispecific Antibody Therapeutics Contract Manufacturing Market 2020 & 2030 (USD Billion)
• FIG 17. Asia pacific Bispecific Antibody Therapeutics Contract Manufacturing Market 2020 & 2030 (USD Billion)
• FIG 18. Latin America Bispecific Antibody Therapeutics Contract Manufacturing Market 2020 & 2030 (USD Billion)
• FIG 19. Middle East & Africa Bispecific Antibody Therapeutics Contract Manufacturing Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Global Bispecific Antibody Therapeutics Contract Manufacturing Market is valued at approximately USD 5.29 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 36.4% over the forecast period 2023-2030. Bispecific antibody therapeutics contract manufacturing refers to the outsourcing of the manufacturing processes involved in producing bispecific antibodies to specialized contract manufacturing organizations (CMOs). Bispecific antibodies are a group of therapeutic molecules created to concurrently target two distinct antigens, which are often located on the surface of cells implicated in illnesses including cancer, autoimmune disorders, and infectious diseases. These antibodies have huge potential due to their capacity to increase therapy specificity and effectiveness. The rise in incidences of chronic diseases such as cancer and autoimmune disorders, surging demand for personalized medicine, as well as globalization of the biopharmaceutical industry are the key factors that are spurring the market demand across the globe.

In addition, a robust pipeline of bispecific antibody therapeutics is witnessing a positive impact on the market growth in the global market. Biopharmaceutical companies often outsource manufacturing to dedicated contract manufacturers to accelerate development timelines in various stages of development. According to BioPharm International, the versatility of bispecific antibody therapeutics extends across various clinical domains such as tumor immunotherapy, neurological disorders, targeted drug delivery, and infectious diseases. As per the BioPharm International, bispecific antibody therapeutics ideally have broad clinical applications in tumor immunotherapy, targeted drug delivery, neurological disorders, or infective diseases. Also, the surge in enthusiasm for bispecific antibody research, coupled with heightened investments in immunotherapy, novel clinical trials, and regulatory approvals is resulting in market expansion. According to the results of the phase I/II clinical trial, individuals with refractory or relapsed multiple myeloma witnessed a 90.5% response rate to the bispecific antibody REGN5459. The outcomes of the bispecific antibody studies in humans were also reported at the annual meeting of the American Association for Cancer Research in 2023. The U.S. FDA has approved the first bispecific antibody targeting BCMA & CD3 for patients with persistent multiple myeloma as a result of the REGN5459 new results. Similarly, according to Sino Biological, Catumaxomab, the first licensed bispecific antibody (bsAB), was among the six bsABs for cancer immunotherapy that the EMA and/or FDA approved as of 2022. Thus, these aforementioned factors are propelling the growth of the bispecific antibody therapeutics Contract Manufacturing Market during the estimated period. Moreover, the ongoing research activities in bispecific antibody therapeutics, as well as technological advancements in biotechnology present various lucrative opportunities over the forecast years. However, the regulatory challenges and the high cost associated with the manufacturing of bispecific antibodies are hampering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Bispecific Antibody Therapeutics Contract Manufacturing Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the high cost of drug development, rising number of clinical trials, technological advancements in biotechnology, and growing research activities. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The increase in demand for bispecific antibodies, rising demand for personalized medicine, coupled with the growing prevalence of cancer and the need for new medications in major countries including China, India, and Japan. are significantly propelling the market demand across the region.

Major market players included in this report are:

• Lonza Group AG
• F. Hoffmann-La Roche Ltd
• Creative Biolabs Inc.
• AbbVie Inc.
• Amgen Inc.
• Janssen Global Services, LLC
• Johnson & Johnson Services, Inc
• IQVIA Holdings Inc.
• WuXi Biologics Holdings Co. Ltd.
• Sino Biological Inc.

Recent Developments in the Market:

• In June 2022, The European Commission issued a conditional marketing authorization for the Roche company's CD20xCD3 T-cell binding bsAB Lunsumio (mosunetuzumab). It is used to treat follicular lymphoma that has relapsed or is resistant among individuals who have already had two systemic therapies.

Global Bispecific Antibody Therapeutics Contract Manufacturing Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Indication, Route of Administration, End-use, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Indication:

• Cancer
• Infectious Diseases
• Autoinflammatory and autoimmune diseases
• CNS Conditions
• Others

By Route of Administration:

• Intravenous
• Subcutaneous
• Others

By End-use:

• Pharmaceutical Companies
• Biopharmaceutical Companies
• Others

By Region:

• North America
• U.S.
• Canada

• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

• Latin America
• Brazil
• Mexico

• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Bispecific Antibody Therapeutics Contract Manufacturing Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Bispecific Antibody Therapeutics Contract Manufacturing Market, by Indication, 2020-2030 (USD Billion)
  • 1.2.3. Bispecific Antibody Therapeutics Contract Manufacturing Market, by Route of Administration, 2020-2030 (USD Billion)
  • 1.2.4. Bispecific Antibody Therapeutics Contract Manufacturing Market, by End-use, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Bispecific Antibody Therapeutics Contract Manufacturing Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Bispecific Antibody Therapeutics Contract Manufacturing Market Dynamics

• 3.1. Bispecific Antibody Therapeutics Contract Manufacturing Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Robust pipeline of bispecific antibody therapeutics
    • 3.1.1.2. Rise in incidences of chronic diseases such as cancer and autoimmune disorders
  • 3.1.2. Market Challenges
    • 3.1.2.1. Regulatory challenges
    • 3.1.2.2. High cost associated with the manufacturing of bispecific antibodies
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Ongoing research activities in bispecific antibody therapeutics
    • 3.1.3.2. Technological advancements in biotechnology

Chapter 4. Global Bispecific Antibody Therapeutics Contract Manufacturing Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Bispecific Antibody Therapeutics Contract Manufacturing Market, by Indication

• 5.1. Market Snapshot
• 5.2. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by Indication, Performance - Potential Analysis
• 5.3. Global Bispecific Antibody Therapeutics Contract Manufacturing Market Estimates & Forecasts by Indication 2020-2030 (USD Billion)
• 5.4. Bispecific Antibody Therapeutics Contract Manufacturing Market, Sub Segment Analysis
  • 5.4.1. Cancer
  • 5.4.2. Infectious Diseases
  • 5.4.3. Autoinflammatory and autoimmune diseases
  • 5.4.4. CNS Conditions
  • 5.4.5. Others

Chapter 6. Global Bispecific Antibody Therapeutics Contract Manufacturing Market, by Route of Administration

• 6.1. Market Snapshot
• 6.2. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by Route of Administration, Performance - Potential Analysis
• 6.3. Global Bispecific Antibody Therapeutics Contract Manufacturing Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
• 6.4. Bispecific Antibody Therapeutics Contract Manufacturing Market, Sub Segment Analysis
  • 6.4.1. Intravenous
  • 6.4.2. Subcutaneous
  • 6.4.3. Others

Chapter 7. Global Bispecific Antibody Therapeutics Contract Manufacturing Market, by End-use

• 7.1. Market Snapshot
• 7.2. Global Bispecific Antibody Therapeutics Contract Manufacturing Market by End-use, Performance - Potential Analysis
• 7.3. Global Bispecific Antibody Therapeutics Contract Manufacturing Market Estimates & Forecasts by End-use 2020-2030 (USD Billion)
• 7.4. Bispecific Antibody Therapeutics Contract Manufacturing Market, Sub Segment Analysis
  • 7.4.1. Pharmaceutical Companies
  • 7.4.2. Biopharmaceutical Companies
  • 7.4.3. Others

Chapter 8. Global Bispecific Antibody Therapeutics Contract Manufacturing Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Bispecific Antibody Therapeutics Contract Manufacturing Market, Regional Market Snapshot
• 8.4. North America Bispecific Antibody Therapeutics Contract Manufacturing Market
  • 8.4.1. U.S. Bispecific Antibody Therapeutics Contract Manufacturing Market
    • 8.4.1.1. Indication breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Route of Administration breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. End-use breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Bispecific Antibody Therapeutics Contract Manufacturing Market
• 8.5. Europe Bispecific Antibody Therapeutics Contract Manufacturing Market Snapshot
  • 8.5.1. U.K. Bispecific Antibody Therapeutics Contract Manufacturing Market
  • 8.5.2. Germany Bispecific Antibody Therapeutics Contract Manufacturing Market
  • 8.5.3. France Bispecific Antibody Therapeutics Contract Manufacturing Market
  • 8.5.4. Spain Bispecific Antibody Therapeutics Contract Manufacturing Market
  • 8.5.5. Italy Bispecific Antibody Therapeutics Contract Manufacturing Market
  • 8.5.6. Rest of Europe Bispecific Antibody Therapeutics Contract Manufacturing Market
• 8.6. Asia-Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market Snapshot
  • 8.6.1. China Bispecific Antibody Therapeutics Contract Manufacturing Market
  • 8.6.2. India Bispecific Antibody Therapeutics Contract Manufacturing Market
  • 8.6.3. Japan Bispecific Antibody Therapeutics Contract Manufacturing Market
  • 8.6.4. Australia Bispecific Antibody Therapeutics Contract Manufacturing Market
  • 8.6.5. South Korea Bispecific Antibody Therapeutics Contract Manufacturing Market
  • 8.6.6. Rest of Asia Pacific Bispecific Antibody Therapeutics Contract Manufacturing Market
• 8.7. Latin America Bispecific Antibody Therapeutics Contract Manufacturing Market Snapshot
  • 8.7.1. Brazil Bispecific Antibody Therapeutics Contract Manufacturing Market
  • 8.7.2. Mexico Bispecific Antibody Therapeutics Contract Manufacturing Market
• 8.8. Middle East & Africa Bispecific Antibody Therapeutics Contract Manufacturing Market
  • 8.8.1. Saudi Arabia Bispecific Antibody Therapeutics Contract Manufacturing Market
  • 8.8.2. South Africa Bispecific Antibody Therapeutics Contract Manufacturing Market
  • 8.8.3. Rest of Middle East & Africa Bispecific Antibody Therapeutics Contract Manufacturing Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Lonza Group AG
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. F. Hoffmann-La Roche Ltd
  • 9.3.3. Creative Biolabs Inc.
  • 9.3.4. AbbVie Inc.
  • 9.3.5. Amgen Inc.
  • 9.3.6. Janssen Global Services, LLC
  • 9.3.7. Johnson & Johnson Services, Inc
  • 9.3.8. IQVIA Holdings Inc.
  • 9.3.9. WuXi Biologics Holdings Co. Ltd.
  • 9.3.10. Sino Biological Inc.

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption